Aspire Biopharma regains compliance with Nasdaq listing requirements

Aspire Biopharma (ASBP) Holdings received a notification letter from The Nasdaq Stock Market confirming that the Company has regained compliance with the minimum stockholders’ equity threshold of $2.5M under Listing Rule 5550(b)(1). The Company announced on February 10, 2026 that it had received a letter from Nasdaq that the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company is now in full compliance with all Nasdaq continued listing requirements and the Company’s common stock will remain listed and traded on the Nasdaq Stock Market. Notwithstanding the compliance determination, the Company was also notified that it will remain subject to a “Panel Monitor,” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the Nasdaq notice, through February 18, 2027. If, during the term of the Panel Monitor, the Company does not continue to remain in compliance with the $2.5M equity requirement, the Company will not be provided with the opportunity to submit a compliance plan for review by the Listing Qualifications Staff and must instead request a hearing before the Panel to address the deficiency, with such request staying any further action with respect to the Company’s listing on Nasdaq pending completion of the hearing process.